Erratum: Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment (Cancer Cell (2017) 32(1) (42–56.e6)(S1535610817302532)(10.1016/j.ccell.2017.06.003));Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment

Cancer Cell

Volumn 32, Issue 1, 2017, Pages 42-56.e6

  Wang, Qianghu ^a   Hu, Baoli ^a   Hu, Xin ^a,b   Kim, Hoon ^a,l   Squatrito, Massimo ^c   Scarpace, Lisa ^d   deCarvalho, Ana C ^d   Lyu, Sali ^e   Li, Pengping ^e   Li, Yan ^e   Barthel, Floris ^a,l   Cho, Hee Jin ^i,j   Lin, Yu Hsi ^a   Satani, Nikunj ^a   Martinez Ledesma, Emmanuel ^a   Zheng, Siyuan ^a   Chang, Edward ^a   Sauvé, Charles Etienne Gabriel ^a   Olar, Adriana ^f   Lan, Zheng D ^a   Finocchiaro, Gaetano ^g   Phillips, Joanna J ^h   Berger, Mitchel S ^h   Gabrusiewicz, Konrad R ^a   Wang, Guocan ^a   Eskilsson, Eskil ^a   Hu, Jian ^a   Mikkelsen, Tom ^e   DePinho, Ronald A ^a   Muller, Florian ^a   Heimberger, Amy B ^a   Sulman, Erik P ^a   Nam, Do Hyun ^i,j,k   Verhaak, Roel G W ^a,l   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d HENRY FORD HOSPITAL   (United States)

^e NANJING MEDICAL UNIVERSITY   (China)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g DEPARTMENT OF NEUROSURGERY   (Italy)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Samsung Medical Center   (South Korea)

^j Sungkyunkwan University   (South Korea)

^k Sungkyunkwan University School of Medicine   (South Korea)

^l JACKSON LABORATORY   (United States)

more..

Author keywords

disease recurrence; glioblastoma; immune cells; macrophages microglia; mesenchymal subtype; proneural to mesenchymal transition; tumor evolution; tumor microenvironment

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; COL1A2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; EPHRIN RECEPTOR B1; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GLIAL FIBRILLARY ACIDIC PROTEIN; HISTONE DEACETYLASE 2; INTEGRIN SUBUNIT ALPHA M; INTERLEUKIN 6; ISOCITRATE DEHYDROGENASE; LOX PROTEIN; MATRILYSIN; MESSENGER RNA; NEUROFIBROMIN; PEPTIDES AND PROTEINS; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; PROTEIN BCL 3; SHORT HAIRPIN RNA; TEMOZOLOMIDE; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR SOX10; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1; TUBULIN; TUMOR MARKER; UNCLASSIFIED DRUG; VDR PROTEIN; VINCULIN;

ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENDRITIC CELL; DNA METHYLATION; EOSINOPHIL; EVOLUTION; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GLIOBLASTOMA; GLIOMA STEM CELL; HELPER CELL; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LONGITUDINAL STUDY; MACROPHAGE; MAST CELL; MEMORY CELL; MEMORY T LYMPHOCYTE; MICROGLIA; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; OVERALL SURVIVAL; PHENOTYPIC PLASTICITY; PLASMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; SURVIVAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTOMICS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; WILD TYPE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY; PHENOTYPE; RECURRENT DISEASE; T LYMPHOCYTE;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; PHENOTYPE; RECURRENCE; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85027444208     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.12.012     Document Type: Erratum

References (71)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.L., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
2. Aran, D., Sirota, M., Butte, A.J., Systematic pan-cancer analysis of tumour purity. Nat. Commun., 6, 2015, 8971.
3. Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Bigner, D.D., Rich, J.N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006), 756–760.
4. Barbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F., Schinzel, A.C., Sandy, P., Meylan, E., Scholl, C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (2009), 108–112.
5. Baysan, M., Bozdag, S., Cam, M.C., Kotliarova, S., Ahn, S., Walling, J., Killian, J.K., Stevenson, H., Meltzer, P., Fine, H.A., G-cimp status prediction of glioblastoma samples using mRNA expression data. PLoS One, 7, 2012, e47839.
6. Bengtsson, H., Ray, A., Spellman, P., Speed, T.P., A single-sample method for normalizing and combining full-resolution copy numbers from multiple platforms, labs and analysis methods. Bioinformatics 25 (2009), 861–867.
7. Bhat, K.P., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J.D., Goodman, L.D., et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24 (2013), 331–346.
8. Blank, C.U., Haanen, J.B., Ribas, A., Schumacher, T.N., Cancer immunology. The “cancer immunogram”. Science 352 (2016), 658–660.
9. Bouffet, E., Larouche, V., Campbell, B.B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34 (2016), 2206–2211.
10. Bowman, R.L., Wang, Q., Carro, A., Verhaak, R.G., Squatrito, M., GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 19 (2017), 139–141.
11. Brennan, C.W., Verhaak, R.G., McKenna, A., Campos, B., Noushmehr, H., Salama, S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., et al. The somatic genomic landscape of glioblastoma. Cell 155 (2013), 462–477.
12. Cancer Genome Atlas Research, Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008), 1061–1068.
13. Cancer Genome Atlas Research Network, Brat, D.J., Verhaak, R.G., Aldape, K.D., Yung, W.K., Salama, S.R., Cooper, L.A., Rheinbay, E., Miller, C.R., Vitucci, M., Morozova, O., et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372 (2015), 2481–2498.
14. Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30 (2012), 413–421.
15. Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray, B.A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M., et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164 (2016), 550–563.
16. Dai, M., Wang, P., Boyd, A.D., Kostov, G., Athey, B., Jones, E.G., Bunney, W.E., Myers, R.M., Speed, T.P., Akil, H., et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res., 33, 2005, e175.
17. Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R.R., Fu, Y.X., Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124 (2014), 687–695.
18. Doucette, T., Rao, G., Rao, A., Shen, L., Aldape, K., Wei, J., Dziurzynski, K., Gilbert, M., Heimberger, A.B., Immune heterogeneity of glioblastoma subtypes: extrapolation from the Cancer Genome Atlas. Cancer Immunol. Res. 1 (2013), 112–122.
19. Dunn, G.P., Rinne, M.L., Wykosky, J., Genovese, G., Quayle, S.N., Dunn, I.F., Agarwalla, P.K., Chheda, M.G., Campos, B., Wang, A., et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26 (2012), 756–784.
20. Engler, J.R., Robinson, A.E., Smirnov, I., Hodgson, J.G., Berger, M.S., Gupta, N., James, C.D., Molinaro, A., Phillips, J.J., Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One, 7, 2012, e43339.
21. Gabrusiewicz, K., Rodriguez, B., Wei, J., Hashimoto, Y., Healy, L.M., Maiti, S.N., Thomas, G., Zhou, S., Wang, Q., Elakkad, A., et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight, 1, 2016, 10.1172/jci.insight.85841.
22. Gill, B.J., Pisapia, D.J., Malone, H.R., Goldstein, H., Lei, L., Sonabend, A., Yun, J., Samanamud, J., Sims, J.S., Banu, M., et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc. Natl. Acad. Sci. USA 111 (2014), 12550–12555.
23. Hambardzumyan, D., Gutmann, D.H., Kettenmann, H., The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 19 (2015), 20–27.
24. Hu, B., Wang, Q., Wang, Y.A., Hua, S., Sauve, C.G., Ong, D., Lan, Z.D., Chang, Q., Ho, Y.W., Monasterio, M.M., et al. Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth. Cell 167 (2016), 1281–1295.e18.
25. Hunter, C., Smith, R., Cahill, D.P., Stephens, P., Stevens, C., Teague, J., Greenman, C., Edkins, S., Bignell, G., Davies, H., et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 66 (2006), 3987–3991.
26. Huse, J.T., Phillips, H.S., Brennan, C.W., Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 59 (2011), 1190–1199.
27. Isella, C., Terrasi, A., Bellomo, S.E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47 (2015), 312–319.
28. Johanns, T.M., Miller, C.A., Dorward, I.G., Tsien, C., Chang, E., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R.E., Dahiya, S., et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 6 (2016), 1230–1236.
29. Joo, K.M., Kim, J., Jin, J., Kim, M., Seol, H.J., Muradov, J., Yang, H., Choi, Y.L., Park, W.Y., Kong, D.S., et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 3 (2013), 260–273.
30. Kim, H., Verhaak, R.G., Transcriptional mimicry by tumor-associated stroma. Nat. Genet. 47 (2015), 307–309.
31. Kim, H., Zheng, S., Amini, S.S., Virk, S.M., Mikkelsen, T., Brat, D.J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 25 (2015), 316–327.
32. Kreutzberg, G.W., Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 (1996), 312–318.
33. Kwon, S.M., Kang, S.H., Park, C.K., Jung, S., Park, E.S., Lee, J.S., Kim, S.H., Woo, H.G., Recurrent glioblastomas reveal molecular subtypes associated with mechanistic implications of drug-resistance. PLoS One, 10, 2015, e0140528.
34. Le, L.Q., Shipman, T., Burns, D.K., Parada, L.F., Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell 4 (2009), 453–463.
35. Lee, J.K., Wang, J., Sa, J.K., Ladewig, E., Lee, H.O., Lee, I.H., Kang, H.J., Rosenbloom, D.S., Camara, P.G., Liu, Z., et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat. Genet. 49 (2017), 594–599.
36. Li, J., Lu, Y., Akbani, R., Ju, Z., Roebuck, P.L., Liu, W., Yang, J.Y., Broom, B.M., Verhaak, R.G., Kane, D.W., et al. TCPA: a resource for cancer functional proteomics data. Nat. Methods 10 (2013), 1046–1047.
37. Martinez, E., Yoshihara, K., Kim, H., Mills, G.M., Trevino, V., Verhaak, R.G., Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. Oncogene 34 (2015), 2732–2740.
38. Mazor, T., Pankov, A., Johnson, B.E., Hong, C., Hamilton, E.G., Bell, R.J., Smirnov, I.V., Reis, G.F., Phillips, J.J., Barnes, M.J., et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28 (2015), 307–317.
39. Meng, Y., Beckett, M.A., Liang, H., Mauceri, H.J., van Rooijen, N., Cohen, K.S., Weichselbaum, R.R., Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 70 (2010), 1534–1543.
40. Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., Alizadeh, A.A., Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12 (2015), 453–457.
41. Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Berman, B.P., Pan, F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 (2010), 510–522.
42. Olar, A., Aldape, K.D., Using the molecular classification of glioblastoma to inform personalized treatment. J. Pathol. 232 (2014), 165–177.
43. Ozawa, T., Riester, M., Cheng, Y., Huse, J.T., Squatrito, M., Helmy, K., Charles, N., Michor, F., Holland, E.C., Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell 26 (2014), 288–300.
44. Palucka, K., Banchereau, J., Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12 (2012), 265–277.
45. Patel, A.P., Tirosh, I., Trombetta, J.J., Shalek, A.K., Gillespie, S.M., Wakimoto, H., Cahill, D.P., Nahed, B.V., Curry, W.T., Martuza, R.L., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344 (2014), 1396–1401.
46. Patro, R., Mount, S.M., Kingsford, C., Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. Nat. Biotechnol. 32 (2014), 462–464.
47. Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Nigro, J.M., Colman, H., Soroceanu, L., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 (2006), 157–173.
48. Prins, R.M., Soto, H., Konkankit, V., Odesa, S.K., Eskin, A., Yong, W.H., Nelson, S.F., Liau, L.M., Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Cancer Res. 17 (2011), 1603–1615.
49. Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson, O.C., Quick, M.L., Huse, J.T., Teijeiro, V., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19 (2013), 1264–1272.
50. Quail, D.F., Bowman, R.L., Akkari, L., Quick, M.L., Schuhmacher, A.J., Huse, J.T., Holland, E.C., Sutton, J.C., Joyce, J.A., The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science, 352, 2016, aad3018.
51. Ries, C.H., Cannarile, M.A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L.P., Feuerhake, F., Klaman, I., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25 (2014), 846–859.
52. Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340 (2013), 626–630.
53. Ruffell, B., Coussens, L.M., Macrophages and therapeutic resistance in cancer. Cancer Cell 27 (2015), 462–472.
54. Sandberg, R., Larsson, O., Improved precision and accuracy for microarrays using updated probe set definitions. BMC Bioinformatics, 8, 2007, 48.
55. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
56. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
57. Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.A., Jones, D.T., Konermann, C., Pfaff, E., Tonjes, M., Sill, M., Bender, S., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22 (2012), 425–437.
58. Sturm, D., Bender, S., Jones, D.T., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J.F., et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat. Rev. Cancer 14 (2014), 92–107.
59. Szulzewsky, F., Arora, S., de Witte, L., Ulas, T., Markovic, D., Schultze, J.L., Holland, E.C., Synowitz, M., Wolf, S.A., Kettenmann, H., Human glioblastoma-associated microglia/monocytes express a distinct RNA profile compared to human control and murine samples. Glia 64 (2016), 1416–1436.
60. Torres-Garcia, W., Zheng, S., Sivachenko, A., Vegesna, R., Wang, Q., Yao, R., Berger, M.F., Weinstein, J.N., Getz, G., Verhaak, R.G., PRADA: pipeline for RNA sequencing data analysis. Bioinformatics 30 (2014), 2224–2226.
61. van den Bent, M.J., Gao, Y., Kerkhof, M., Kros, J.M., Gorlia, T., van Zwieten, K., Prince, J., van Duinen, S., Sillevis Smitt, P.A., Taphoorn, M., French, P.J., Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol. 17 (2015), 935–941.
62. van Vulpen, M., Kal, H.B., Taphoorn, M.J., El-Sharouni, S.Y., Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol. Rep. 9 (2002), 683–688.
63. Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 (2010), 98–110.
64. Wang, L., Feng, Z., Wang, X., Wang, X., Zhang, X., DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics 26 (2010), 136–138.
65. Xu, S., Wei, J., Wang, F., Kong, L.Y., Ling, X.Y., Nduom, E., Gabrusiewicz, K., Doucette, T., Yang, Y., Yaghi, N.K., et al. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J. Natl. Cancer Inst., 106, 2014, 10.1093/jnci/dju162.
66. Yan, J., Kong, L.Y., Hu, J., Gabrusiewicz, K., Dibra, D., Xia, X., Heimberger, A.B., Li, S., FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. J. Natl. Cancer Inst., 107, 2015, 10.1093/jnci/djv137.
67. Ye, X.Z., Xu, S.L., Xin, Y.H., Yu, S.C., Ping, Y.F., Chen, L., Xiao, H.L., Wang, B., Yi, L., Wang, Q.L., et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J. Immunol. 189 (2012), 444–453.
68. Yoshihara, K., Shahmoradgoli, M., Martinez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Trevino, V., Shen, H., Laird, P.W., Levine, D.A., et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun., 4, 2013, 2612.
69. Zeng, J., See, A.P., Phallen, J., Jackson, C.M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T.J., Albesiano, E., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86 (2013), 343–349.
70. Zhang, Y., Sloan, S.A., Clarke, L.E., Caneda, C., Plaza, C.A., Blumenthal, P.D., Vogel, H., Steinberg, G.K., Edwards, M.S., Li, G., et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89 (2016), 37–53.
71. Zheng, S., Chheda, M.G., Verhaak, R.G., Studying a complex tumor: potential and pitfalls. Cancer J. 18 (2012), 107–114.